Heart Failure Benefit
Anchor lead: Two diabetes drugs may benefit people with heart failure, Elizabeth Tracey reports
A diabetes drug with the tongue-twisting name ‘empagliflozin’ reduced both hospitalizations for heart failure as well as cardiovascular death in people with one type of heart failure, a study known by the acronym EMPEROR has found. Rita Kalyani, a diabetes expert at Johns Hopkins, says the results are consistent with previous research.
Kalyani: Some agents in the newer classes, GLP1 receptor agonists and SGLT2 inhibitors, have superiority in reducing cardiovascular events in those who are at high risk or have previous history of cardiovascular disease. What was interesting about the EMPEROR trial was that they were looking at heart failure hospitalizations or cardiovascular death in people who had diabetes or did not have diabetes. So it was exciting because it was not just people with diabetes but also people without. :31
Kalyani says the benefit in those with heart failure but without diabetes was novel and needs to be confirmed. At Johns Hopkins, I’m Elizabeth Tracey.